DUOLAC, K-Probiotics has ranked No.1 in global exports for 12 consecutive years

DUOLAC, a probiotic brand by Cell Biotech made in Korea, has achieved the No.1 position in South Korea’s probiotic exports for the 12th consecutive year. Since 2013, DUOLAC has held the top spot annually, firmly establishing itself as a key driver in the globalization of Korean probiotics, also known as "K-Probiotics."

According to the 2024 Food and Supplement Production Statistics released by the Ministry of Food and Drug Safety, South Korea’s total probiotic exports in 2023 reached 58.4 billion KRW. Of that, Cell Biotech accounted for approximately 25.9 billion KRW, commanding over 44% of the total market - an overwhelming lead.

Cell Biotech’s success is largely attributed to its proactive international expansion strategy. Early on, the company established a local subsidiary in Denmark to target the European market, and now exports to 55 countries across Asia and Europe. DUOLAC holds the No.2 market share in Denmark, and is ranked No.1 in both Singapore and Indonesia. Notably, cumulative exports to Indonesia recently surpassed $30 million.

Another cornerstone of Cell Biotech’s leadership is its proprietary technology. Backed by 30 years of expertise and its own Korean-developed CBT probiotic strains, the company voluntarily complies with rigorous global safety standards - including GRAS registration with the U.S. FDA, genome analysis, antibiotic resistance testing, and toxic gene screenings.

DUOLAC’s patented Dual Coating Technology ensures probiotics survive harsh conditions and effectively reach the intestines - even within the spicy Korean diet. Clinical studies have demonstrated that CBT probiotics used in DUOLAC achieve up to 221 times higher intestinal survival rates compared to uncoated probiotics.

Cell Biotech also boasts a robust R&D pipeline, with 124 academic publications and 107 registered patents. The company is currently conducting clinical trials for PP-P8, an innovative CBT probiotic drug candidate targeting colorectal cancer - further solidifying its global leadership in probiotic development and production.

Through personalized probiotic solutions tailored to different life stages - from newborns to older adults - DUOLAC delivers health benefits that extend far beyond Korea to consumers around the world.

A company spokesperson stated, “Our goal has never been just export volume—we strive to contribute to global health and well-being. This 12-year milestone reflects our dedication to innovation, quality, and trust.”